Biocon to expand generic drugs business with DKSH

As a part of the pact, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon’s brand in these key Asian markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Bsbx7F
via IFTTT